An Expedition on Synthetic Methodology of FDA-approved Anticancer Drugs (2018-2021)
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
New drugs being established in the market every year produce specified structures for selective biological targeting. With medicinal insights into molecular recognition, these begot molecules open new rooms for designing potential new drug molecules. In this review, we report the compilation and analysis of a total of 56 drugs including 33 organic small molecules (Mobocertinib, Infigratinib, Sotorasib, Trilaciclib, Umbralisib, Tepotinib, Relugolix, Pralsetinib, Decitabine, Ripretinib, Selpercatinib, Capmatinib, Pemigatinib, Tucatinib, Selumetinib, Tazemetostat, Avapritinib, Zanubrutinib, Entrectinib, Pexidartinib, Darolutamide, Selinexor, Alpelisib, Erdafitinib, Gilteritinib, Larotrectinib, Glasdegib, Lorlatinib, Talazoparib, Dacomitinib, Duvelisib, Ivosidenib, Apalutamide), 6 metal complexes (Edotreotide Gallium Ga-68, fluoroestradiol F-18, Cu 64 dotatate, Gallium 68 PSMA-11, Piflufolastat F-18, 177Lu (lutetium)), 16 macromolecules as monoclonal antibody conjugates (Brentuximabvedotin, Amivantamab-vmjw, Loncastuximabtesirine, Dostarlimab, Margetuximab, Naxitamab, Belantamabmafodotin, Tafasitamab, Inebilizumab, SacituzumabGovitecan, Isatuximab, Trastuzumab, Enfortumabvedotin, Polatuzumab, Cemiplimab, Mogamulizumab) and 1 peptide enzyme (Erwiniachrysanthemi-derived asparaginase) approved by the U.S. FDA between 2018 to 2021. These drugs act as anticancer agents against various cancer types, especially non-small cell lung, lymphoma, breast, prostate, multiple myeloma, neuroendocrine tumor, cervical, bladder, cholangiocarcinoma, myeloid leukemia, gastrointestinal, neuroblastoma, thyroid, epithelioid and cutaneous squamous cell carcinoma. The review comprises the key structural features, approval times, target selectivity, mechanisms of action, therapeutic indication, formulations, and possible synthetic approaches of these approved drugs. These crucial details will benefit the scientific community for futuristic new developments in this arena.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
---|---|
Enthalten in: |
Anti-cancer agents in medicinal chemistry - (2024) vom: 29. Jan. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
S, Vishakha [VerfasserIn] |
---|
Links: |
---|
Themen: |
Anticancer agents. |
---|
Anmerkungen: |
Date Revised 30.01.2024 published: Print-Electronic Citation Status Publisher |
---|
doi: |
10.2174/0118715206259585240105051941 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM367791595 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM367791595 | ||
003 | DE-627 | ||
005 | 20240130232300.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240130s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.2174/0118715206259585240105051941 |2 doi | |
028 | 5 | 2 | |a pubmed24n1275.xml |
035 | |a (DE-627)NLM367791595 | ||
035 | |a (NLM)38288815 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a S, Vishakha |e verfasserin |4 aut | |
245 | 1 | 3 | |a An Expedition on Synthetic Methodology of FDA-approved Anticancer Drugs (2018-2021) |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 30.01.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status Publisher | ||
520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
520 | |a New drugs being established in the market every year produce specified structures for selective biological targeting. With medicinal insights into molecular recognition, these begot molecules open new rooms for designing potential new drug molecules. In this review, we report the compilation and analysis of a total of 56 drugs including 33 organic small molecules (Mobocertinib, Infigratinib, Sotorasib, Trilaciclib, Umbralisib, Tepotinib, Relugolix, Pralsetinib, Decitabine, Ripretinib, Selpercatinib, Capmatinib, Pemigatinib, Tucatinib, Selumetinib, Tazemetostat, Avapritinib, Zanubrutinib, Entrectinib, Pexidartinib, Darolutamide, Selinexor, Alpelisib, Erdafitinib, Gilteritinib, Larotrectinib, Glasdegib, Lorlatinib, Talazoparib, Dacomitinib, Duvelisib, Ivosidenib, Apalutamide), 6 metal complexes (Edotreotide Gallium Ga-68, fluoroestradiol F-18, Cu 64 dotatate, Gallium 68 PSMA-11, Piflufolastat F-18, 177Lu (lutetium)), 16 macromolecules as monoclonal antibody conjugates (Brentuximabvedotin, Amivantamab-vmjw, Loncastuximabtesirine, Dostarlimab, Margetuximab, Naxitamab, Belantamabmafodotin, Tafasitamab, Inebilizumab, SacituzumabGovitecan, Isatuximab, Trastuzumab, Enfortumabvedotin, Polatuzumab, Cemiplimab, Mogamulizumab) and 1 peptide enzyme (Erwiniachrysanthemi-derived asparaginase) approved by the U.S. FDA between 2018 to 2021. These drugs act as anticancer agents against various cancer types, especially non-small cell lung, lymphoma, breast, prostate, multiple myeloma, neuroendocrine tumor, cervical, bladder, cholangiocarcinoma, myeloid leukemia, gastrointestinal, neuroblastoma, thyroid, epithelioid and cutaneous squamous cell carcinoma. The review comprises the key structural features, approval times, target selectivity, mechanisms of action, therapeutic indication, formulations, and possible synthetic approaches of these approved drugs. These crucial details will benefit the scientific community for futuristic new developments in this arena | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a FDA-approved anticancer drugs | |
650 | 4 | |a anticancer agents. | |
650 | 4 | |a synthetic approaches | |
650 | 4 | |a target selectivity | |
700 | 1 | |a N, Navneesh |e verfasserin |4 aut | |
700 | 1 | |a Kurmi, Balak Das |e verfasserin |4 aut | |
700 | 1 | |a Das Gupta, Ghanshyam |e verfasserin |4 aut | |
700 | 1 | |a Verma, Sant Kumar |e verfasserin |4 aut | |
700 | 1 | |a Jain, Ankit |e verfasserin |4 aut | |
700 | 1 | |a Patel, Preeti |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Anti-cancer agents in medicinal chemistry |d 2006 |g (2024) vom: 29. Jan. |w (DE-627)NLM160693403 |x 1875-5992 |7 nnns |
773 | 1 | 8 | |g year:2024 |g day:29 |g month:01 |
856 | 4 | 0 | |u http://dx.doi.org/10.2174/0118715206259585240105051941 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |j 2024 |b 29 |c 01 |